Outcome MeasureMystical Experience

HRS

Hallucinogen Rating Scale

4 Papers in Blossom

Outcome Data Across Studies

Reported results for HRS across 4 studies with quantitative data.

Outcome data across 8 study arm–timepoint observations
SD
Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up
2002Secondary
High dose ketamine(experimental)7—1.80.50.001
Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up
2002Secondary
Low dose ketamine(active_comparator)7—1.10.50.001
Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study
2015Secondary
Psilocybin(experimental)0.292102.41.0—
Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study
2015Secondary
Psilocybin(experimental)0.29262.01.1—
Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction
2015Secondary
Psilocybin-assisted; abstinent at 6 months(experimental)0122.5——
Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction
2015Secondary
Psilocybin-assisted; still smoking at 6 months(experimental)032.5——
The psychedelic debriefing in alcohol dependence treatment: illustrating key change phenomena through qualitative content analysis of clinical sessions
2018Secondary
Psilocybin(experimental)0102.41.0—
The psychedelic debriefing in alcohol dependence treatment: illustrating key change phenomena through qualitative content analysis of clinical sessions
2018Secondary
Psilocybin(experimental)2862.01.1—

Papers Using HRS

Open Accessindividual

The psychedelic debriefing in alcohol dependence treatment: illustrating key change phenomena through qualitative content analysis of clinical sessions

This open-label pilot study (n=10) of psilocybin-assisted treatment of alcohol dependence (21mg/70kg) presents a qualitative content analysis of the 17 debriefing sessions conducted in the pilot study, which occurred the day after corresponding psilocybin medication sessions. Participants articulated a series of key phenomena related to change in drinking outcomes and acute subjective effects of psilocybin.

Published
Journal
Frontiers in Pharmacology
Authors
Kraehenmann, R., Nielson, E. M., May, D. G., Forcehimes, A. A., Bogenschutz, M. P.
Open Accessindividual

Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction

This follow-up study (n=15) to an open-label pilot-study of psilocybin-facilitated smoking addiction treatment found that the mystical experience (MEQ) but not the intensity of the experience was predictive of smoking abstinence (80% at 6-month follow-up).

Published
Journal
Current Drug Abuse Reviews
Authors
Garcia-Romeu, A., Griffiths, R. R., Johnson, M. W.
Open Accessindividual

Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study

In a single-group proof-of-concept study of 10 participants with DSM‑IV alcohol dependence, psilocybin administered alongside motivational enhancement therapy produced a significant increase in abstinence after dosing that was largely maintained to 36 weeks, with the intensity of the first session strongly predicting subsequent reductions in drinking, craving and increased abstinence self‑efficacy. There were no significant treatment‑related adverse events, supporting the need for larger controlled trials to evaluate efficacy and mechanisms.

Published
Journal
Journal of Psychopharmacology
Authors
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., Strassman, R. J.
Open Accessindividual

Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up

This randomised double-blind clinical trial (2002, n=70) found that existential psychotherapy in combination with psychedelic doses of intramuscular (im) ketamine (140mg/70kg) achieved larger results in the treatment of heroin addiction than sub-hallucinogenic doses (14mg/70kg).

Published
Journal
Journal of Substance Abuse Treatment
Authors
Krupitsky, E. M., Burakov, A. M., Romanova, T. N., Dunaevsky, I. V., Strassman, R. J., Grinenko, A. Y.

Quick Facts

Full Name
Hallucinogen Rating Scale
Domain
Mystical Experience
Papers Indexed
4
Interpretation
Higher = better
All Measures